Citadel Advisors’s Albireo Pharma Inc ALBO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-2,169
| Closed | -$46.9K | – | 16088 |
|
|
2022
Q4 | $46.9K | Sell |
2,169
-247,302
| -99% | -$5.23M | ﹤0.01% | 12212 |
|
|
2022
Q3 | $4.83M | Buy |
249,471
+127,950
| +105% | +$2.65M | ﹤0.01% | 3931 |
|
|
2022
Q2 | $2.41M | Buy |
121,521
+23,515
| +24% | +$620K | ﹤0.01% | 5179 |
|
|
2022
Q1 | $2.92M | Buy |
98,006
+69,163
| +240% | +$2.02M | ﹤0.01% | 5248 |
|
|
2021
Q4 | $672K | Buy |
28,843
+10,872
| +60% | +$289K | ﹤0.01% | 8934 |
|
|
2021
Q3 | $561K | Sell |
17,971
-2,964
| -14% | -$91.7K | ﹤0.01% | 9590 |
|
|
2021
Q2 | $736K | Buy |
+20,935
| New | +$681K | ﹤0.01% | 9141 |
|
|
2021
Q1 | – | Sell |
-22,472
| Closed | -$830K | – | 13902 |
|
|
2020
Q4 | $843K | Sell |
22,472
-118,349
| -84% | -$4.3M | ﹤0.01% | 7152 |
|
|
2020
Q3 | $4.7M | Buy |
140,821
+122,926
| +687% | +$3.58M | ﹤0.01% | 3259 |
|
|
2020
Q2 | $474K | Buy |
17,895
+7,105
| +66% | +$168K | ﹤0.01% | 7176 |
|
|
2020
Q1 | $177K | Buy |
+10,790
| New | +$237K | ﹤0.01% | 8135 |
|
|
2016
Q4 | – | Sell |
-1,572
| Closed | -$20K | – | 8032 |
|
|
2016
Q3 | $20K | Sell |
1,572
-900
| -36% | -$10.6K | ﹤0.01% | 7051 |
|
|
2016
Q2 | $23K | Buy |
2,472
+2,086
| +540% | +$23K | ﹤0.01% | 6573 |
|
|
2016
Q1 | $4K | Sell |
386
-1,657
| -81% | -$14.7K | ﹤0.01% | 6631 |
|
|
2015
Q4 | $21K | Buy |
2,043
+1,914
| +1,484% | +$19.8K | ﹤0.01% | 7899 |
|
|
2015
Q3 | $2K | Sell |
129
-104
| -45% | -$2.62K | ﹤0.01% | 8752 |
|
|
2015
Q2 | $7K | Sell |
233
-428
| -65% | -$14.4K | ﹤0.01% | 8484 |
|
|
2015
Q1 | $24K | Sell |
661
-419
| -39% | -$17.7K | ﹤0.01% | 7802 |
|
|
2014
Q4 | $43K | Buy |
1,080
+643
| +147% | +$28.2K | ﹤0.01% | 7309 |
|
|
2014
Q3 | $22K | Buy |
+437
| New | +$25.1K | ﹤0.01% | 7366 |
|
|
2014
Q2 | – | Sell |
-333
| Closed | -$27K | – | 8414 |
|
|
2014
Q1 | $27K | Buy |
333
+124
| +59% | +$11.3K | ﹤0.01% | 7150 |
|
|
2013
Q4 | $14K | Sell |
209
-409
| -66% | -$30K | ﹤0.01% | 6629 |
|
|
2013
Q3 | $58K | Sell |
618
-186
| -23% | -$24.2K | ﹤0.01% | 5704 |
|
|
2013
Q2 | $101K | Buy |
+804
| New | +$83.7K | ﹤0.01% | 5227 |
|
Other funds holding ALBO
Citadel Advisors's ALBO Position: Q1 2023 in Review
Citadel Advisors sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 2,169 shares — an estimated $46.9K sold.
Citadel Advisors first reported a position in ALBO in Q2 2013 and held it in 24 quarters. The position peaked at $4.83M in Q3 2022. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.
- Citadel Advisors reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
- Citadel Advisors sold 2,169 Albireo Pharma Inc shares in Q1 2023, an estimated $46.9K.
- Citadel Advisors first reported a position in Albireo Pharma Inc in Q2 2013 and held it in 24 quarters.
- Citadel Advisors's Albireo Pharma Inc position peaked at $4.83M in Q3 2022.
- 3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.
Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.